P3-TOPAX ECO

Glavne informacije

  • Zaščiteno ime:
  • P3-TOPAX ECO (905751)
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • P3-TOPAX ECO (905751)
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 115915E
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila

P3-topax ECO

VARNOSTNI LIST

Ime proizvoda

P3-topax ECO

V skladu z Uredbo (ES) št. 1907/2006 (REACH), Priloga II (453/2010) - Evropa

:

1.1 Identifikator izdelka

1.3 Podrobnosti o dobavitelju varnostnega lista

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Navedene uporabe

ODDELEK 1: Identifikacija snovi/zmesi in družbe/podjetja

Šifra proizvoda

:

Odsvetujejo se načini uporabe

1.4 Telefonska številka za nujne primere

Nacionalno posvetovalno telo/Center za zastrupitve

Sredstvo za čiščenje s peno. Polavtomatski postopek z ventilacijo

Sredstvo za čiščenje s peno. Polavtomatski postopek brez ventilacije

Ni znano.

Ecolab d.o.o.

Vajngerlova 4

SI-2000 Maribor

Slovenija

Tel.: +386 (0)2 42 93 100

Št. faksa: +386 (0)2 42 93 152

office.maribor@ecolab.com

:

Proizvajalec/ Distributer/

Uvoznik

115915E

Uporaba proizvoda

:

Čistilo

Proizvod je samo za profesionalno uporabo.

Proizvajalec/ Distributer/ Uvoznik

:

Številka telefona

Navodilo v primeru zdravstvene ogroženosti: nemudoma se posvetovati z osebnim

ali dežurnim zdravnikom, le v primeru življenjske ogroženosti poklicati 112.

:

Številka telefona

Tel.: +386 (0)2 42 93 100 (Uradne ure ob delavnikih: 8:00 – 15:00)

Verzija

: 1

Razvrstitev

C; R35

Razvrstitev temelji izključno na pH vrednosti proizvoda (skladno z veljavno evropsko

zakonodajo).

:

:

Nevarnosti za človeka

Povzroča hude opekline.

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptomih.

Razvrstitev skladno z Uredbo (ES) 1272/2008 [CLP/GHS]

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Opredelitev izdelka

:

Zmes

Glej Oddelek 16 za celotno besedilo zgoraj navedenih stavkov R ali H.

Razvrstitev v skladu z Direktivo 1999/45/ES [DSD]

Proizvod je razvrščen kot nevaren v skladu z Direktivo 1999/45/ES in njenimi dopolnitvami.

2.2 Elementi etikete

Skin Corr. 1, H314

Datum izdaje/Datum

revidirane izdaje

:

1/13

21 Januar 2014

P3-topax ECO

ODDELEK 2: Ugotovitev nevarnosti

:

Ostale nevarnosti, ki

nimajo vpliva na

razvrstitev

Piktogrami za nevarnosti

:

Opozorilna beseda

:

Stavki o nevarnosti

:

Preprečevanje

:

Previdnostni stavki

Odziv

:

Nevarno

P280 - Nositi zaščitne rokavice in zaščito za oči/obraz.

P303 + P361 + P353 - PRI STIKU S KOŽO (ali lasmi): Takoj sleči vso onesnaženo

obleko. Kožo sprati z vodo ali prho.

P305 + P351 + P338 - PRI STIKU Z OČMI: Previdno izpirati z vodo nekaj minut.

Odstranite kontaktne leče, če jih imate in če to lahko storite brez težav. Nadaljujte z

izpiranjem.

P310 - Takoj pokličite CENTER ZA ZASTRUPITVE ali zdravnika.

2.3 Druge nevarnosti

Vsebuje

:

Ni primerno.

Etilendiamintetraacetat

Natrijev hidroksid

Alkilaminoksidi

H314

Povzroča hude opekline kože in poškodbe oči.

Proizvod ne vsebuje dodatnih sestavin, ki bi bile, glede na trenutno znane podatke, ki so na voljo dobavitelju in v

primernih koncentracijah, razvrščene kot zdravju ali okolju nevarne in ki bi jih bilo potrebno navajati v tem oddelku.

ODDELEK 3: Sestava/podatki o sestavinah

Identifikatorji

67/548/EGS

Ime ali trgovsko ime

izdelka/snovi

Glej Oddelek 16 za

celotno besedilo

zgoraj navedenih R

stavkov

%

Tip

Uredba (ES) št.

1272/2008 [CLP]

Razvrstitev

Glej Oddelek 16 za

celotno besedilo

zgoraj navedenih

stavkov o nevarnosti

H.

Etilendiamintetraacetat

REACH #:

01-2119486762-27

EC: 200-573-9

CAS: 64-02-8

Indeks: 607-428-00-2

10 -

<20

Xn; R20/22

Xi; R41

Acute Tox. 4, H302

Eye Dam. 1, H318

Natrijev hidroksid

REACH #:

01-2119457892-27

EC: 215-185-5

CAS: 1310-73-2

Indeks: 011-002-00-6

2 - <5

C; R35

Skin Corr. 1A, H314

[1] [2]

Alkilaminoksidi

EC: 273-281-2

CAS: 68955-55-5

1 - <5

Xi; R41, R38

N; R50

Skin Irrit. 2, H315

Eye Dam. 1, H318

Aquatic Acute 1, H400

Arilsulfonati

EC: 235-088-1

CAS: 12068-03-0

<10

Xi; R36

Eye Irrit. 2, H319

Zmesi

3.2

Datum izdaje/Datum

revidirane izdaje

:

2/13

21 Januar 2014

P3-topax ECO

ODDELEK 3: Sestava/podatki o sestavinah

Mejne vrednosti izpostavitve pri delu, če so na voljo, so navedene v oddelku 8.

[1] Snov razvrščena kot nevarna za zdravje ali okolje

[2] Snov za katero obstajajo mejne vrednosti za poklicno izpostavljenost

[3] Snov izpolnjuje merila za PBT skladno z Uredbo (ES) št. 1907/2006, priloga XIII.

[4] Snov izpolnjuje merila za vPvB skladno z Uredbo (ES) št. 1907/2006, priloga XIII.

[5] Snov, ki vzbuja enakovredno zaskrbljenost

Usta sprati z vodo. Če ima ponesrečenec zobno protezo, jo je potrebno odstraniti.

Če je snov bila zaužita in je ponerečenec pri zavesti, dajati manjše količine vode za

pitje. Prenehati, če se ponesrečeni počuti slabo, ker je bruhanje nevarno. Ne

sprožiti bruhanja, razen po navodilih zdravniškega osebja. Ob bruhanju držite

glavo v nizkem položaju, da izbljuvek ne vstopi v pljuča. Opekline zaradi kemikalij

mora nemudoma oskrbeti zdravnik. Nikoli ničesar dajati v usta nezavestni osebi.

Nezavestnega spraviti v bočni položaj in nemudoma poklicati zdravniško pomoč.

Vzdrževati proste dihalne poti. Zrahljati oblačila npr. ovratnik, kravato ali pas.

Prenesti ponesrečenca na svež zrak in ga pustiti počivati v položaju, ki olajša

dihanje. Takoj poiskati zdravniško pomoč. Pokličite center za zastrupitve ali

zdravnika.

Stik s kožo

Oči takoj izpirati z obilo vode, občasno dvigniti zgornjo in spodnjo veko. Preveriti, ali

ima ponesrečenec kontaktne leče in jih odstraniti . Spirati vsaj 15 minut. Opekline

zaradi kemikalij mora nemudoma oskrbeti zdravnik. Takoj poiskati zdravniško

pomoč. Pokličite center za zastrupitve ali zdravnika.

Onesnažen predel kože izprati z obilo vode. Odstraniti onesnažena oblačila in

obutev. Spirati vsaj 15 minut. Opekline zaradi kemikalij mora nemudoma oskrbeti

zdravnik. Oprati onesnažena oblačila pred ponovno uporabo. Temeljito očistiti

čevlje pred ponovno uporabo. Takoj poiskati zdravniško pomoč. Pokličite center za

zastrupitve ali zdravnika.

4.1 Opis ukrepov za prvo pomoč

Prenesti ponesrečenca na svež zrak in ga pustiti počivati v položaju, ki olajša

dihanje. Če ponesrečenec ne diha, če diha neredno, ali če je prišlo do ustavitve

dihanja, naj mu usposobljena oseba daje umetno dihanje ali kisik. Nezavestnega

spraviti v bočni položaj in nemudoma poklicati zdravniško pomoč. Vzdrževati proste

dihalne poti. Zrahljati oblačila npr. ovratnik, kravato ali pas. Pri vdihavanju

produktov razkroja v požaru so lahko simptomi zakasnjeni. Takoj poiskati

zdravniško pomoč. Pokličite center za zastrupitve ali zdravnika.

Zaužitje

Vdihavanje

Stik z očmi

:

:

:

:

Zaščita osebja za prvo

pomoč

:

ODDELEK 4: Ukrepi za prvo pomoč

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Potencialno akutni vplivi na zdravje

Vdihavanje

:

Lahko sprošča pline, hlape ali prah, ki so zelo dražilni ali jedki za dihalni sistem.

Izpostavljenost produktom razkroja lahko ogrozi zdravje. Resne posledice, ki sledijo

izpostavitvi, so lahko pojavijo z zakasnitvijo.

Jedko za prebavni trakt. Povzroča opekline. Lahko povzroči opekline ust, žrela in

želodca.

:

Zaužitje

Stik s kožo

:

Povzroča hude opekline.

Povzroča hude poškodbe oči.

:

Stik z očmi

Znaki/simptomi prekomerne izpostavljenosti

Do ukrepanja ne bo prišlo, če ima za posledico osebno tveganje ali osebje ni

predhodno ustrezno šolano. Preden se jih odstrani, onesnažena oblačila temeljito

sprati z vodo ali nositi zaščitne rokavice.

Datum izdaje/Datum

revidirane izdaje

:

3/13

21 Januar 2014

P3-topax ECO

ODDELEK 4: Ukrepi za prvo pomoč

Opombe za zdravnika

Pri vdihavanju produktov razkroja v požaru so lahko simptomi zakasnjeni.

:

Posebno ravnanje

Stik s kožo

Zaužitje

Vdihavanje

Škodljivi simptomi lahko vključujejo naslednje:

draženje dihalnih poti

kašljanje

Škodljivi simptomi lahko vključujejo naslednje:

bolečine v želodcu

Škodljivi simptomi lahko vključujejo naslednje:

bolečina ali draženje

pordelost

lahko se pojavijo mehurji

:

:

:

Stik z očmi

:

Škodljivi simptomi lahko vključujejo naslednje:

bolečina

solzenje

pordelost

4.3 Navedba kakršne koli takojšnje medicinske oskrbe in posebnega zdravljenja

Ni specifičnega zdravljenja.

:

V primeru požara, evakuirati območje. Do ukrepanja ne bo prišlo, če ima za

posledico osebno tveganje ali osebje ni predhodno ustrezno šolano.

Nevarni produkti

izgorevanja

Nevarnosti zaradi snovi ali

zmesi.

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikov dioksid

ogljikov monoksid

dušikovi oksidi

žveplovi oksidi

kovinski oksid/oksidi

Pri požaru ali segrevanju, se tlak poveča in posoda lahko poči.

Gasilci morajo nositi primerno zaščitno opremo in samostojni dihalni aparat (SCBA)

z masko, ki pokriva celoten obraz in ima pozitiven tlak.

Navedba posebne

varovalne opreme za

gasilce

V primeru požara uporabiti razpršeno vodo (meglica), peno, suha gasilna sredstva

ali CO2.

5.1 Sredstva za gašenje

:

:

:

Ni znano.

Ustrezna sredstva za

gašenje

:

Neustrezna sredstva za

gašenje

:

ODDELEK 5: Protipožarni ukrepi

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

5.3 Nasvet za gasilce

Posebni previdnostni

ukrepi za gasilce

:

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

Za osebje. ki ni nujno

:

Do ukrepanja ne bo prišlo, če ima za posledico osebno tveganje ali osebje ni

predhodno ustrezno šolano. Preprečiti dostop odvečnim in nezaščitenim osebam.

Poskusite se izogniti stiku ali hoji preko razlitega materiala. Preprečiti vdihavanje

hlapov ali meglic. Zagotoviti zadostno prezračevanje. Če je prezračevanje

nezadostno, nositi ustrezno opremo za dihanje. Nositi ustrezno osebno zaščitno

opremo.

Datum izdaje/Datum

revidirane izdaje

:

4/13

21 Januar 2014

P3-topax ECO

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.2 Okoljevarstveni ukrepi

Zaustaviti razlitje, če to ne predstavlja tveganja. Odmakniti embalažo z mesta

razlitja. Bližnji izpust v obratni smeri vetra. Preprečiti iztekanje v kanalizacijo,

vodotoke, kleti ali zaprte prostore. Sperite razlitja v obrat za obdelavo odpadnih vod

ali ravnajte kot sledi. Zadržati in zbrati razlit material z nevnetljivimi absorpcijskimi

materiali, npr. peskom, prstjo, vermikulitom, diatomejsko zemljo, in namestiti v

embalažo za odstranjevanje v skladu s predpisi. Onesnažen absorpcijski material

predstavlja enako nevarnost kot razliti proizvod.

Preprečiti, da bi se razlit oz. razsut tovor razširil; preprečiti stik s tlemi, vodotoki,

cestno kanalizacijo in odplakami. Če je prišlo do onesnaženja okolja (kanalizacije,

vodotokov, tal ali zraka), obvestiti pristojne službe.

Obsežno razlitje

:

Zaustaviti razlitje, če to ne predstavlja tveganja. Odmakniti embalažo z mesta

razlitja. Če je topno v vodi, razredčiti z vodo in pobrisati. Po drugi strani, oziroma če

ni topno v vodi, vsrkati z inertno suho snovjo in namestiti v ustrezno embalažo za

odstranjevanje odpadkov.

Majhno razlitje

:

6.3 Metode in materiali za zadrževanje in čiščenje

Za reševalce

:

6.4 Sklicevanje na druge

oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Glej Oddelek 8 za podatke o ustrezni zaščitni opremi.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

Če so pri rokovanju z razlitjem zahtevana specialna oblačila, upoštevati podatke o

primernih in neprimernih materialih v Oddelku 8. Glej tudi informacije pod "Za

neizučeno osebje".

:

:

Skladiščiti med sledečima temperaturama: -5 do 40°C (23 do 104°F). Skladiščiti

skladno z lokalno zakonodajo. Skladiščiti v originalni embalaži, zaščiteno pred

direktno sončno svetlobo v suhem, hladnem in dobro prezračevanem prostoru,

ločeno od nezdružljivih snovi (glej Oddelek 10) ter hrane in pijače. Hraniti ločeno od

kislin. Do uporabe hraniti posodo tesno zaprto in zatesnjeno. Odprto embalažo

previdno zatesniti in držati v pokončnem položaju, da se prepreči iztekanje. Ne

hraniti v neoznačeni embalaži. S primernim ravnanjem preprečiti onesnaževanje

okolja.

ODDELEK 7: Ravnanje in skladiščenje

Informacije v tem oddelku vsebujejo splošne nasvete in napotke. Glede specifične uporabe je za podatke, ki so na

voljo v scenariju(ih) izpostavljenosti, potrebno upoštevati seznam identificiranih uporab v Oddelku 1.

7.1 Varnostni ukrepi za varno ravnanje

Zaščitni ukrepi

:

Nasvet glede splošne

poklicne higiene

:

7.2 Pogoji za varno

skladiščenje, vključno z

nezdružljivostjo

7.3 Posebne končne uporabe

Nositi ustrezno osebno zaščitno opremo. (Glej Oddelek 8) Preprečiti stik z očmi,

kožo ali oblačili. Preprečiti vdihavanje hlapov ali meglic. Ne zaužiti. Če snov pri

običajni uporabi predstavlja nevarnost za dihanje, se jo sme uporabljati le v

primerno prezračevanem prostoru ali ob uporabi ustreznega dihalnega aparata.

Hraniti v originalni embalaži ali odobrenem nadomestilu iz ustreznega materiala;

kadar se ne uporablja, mora biti tesno zaprto. Ne izpostavljati kislinam.

Pred jedjo, pitjem ali kajenjem si je potrebno umiti roke in obraz. Glej Oddelek 8 za

dodatne podatke glede higienskih ukrepov.

:

Razred skladiščenja

:

Rešitve, specifične za

industrijsko panogo

:

Ni primerno dokler ni na razpolago scenarijev izpostavljenosti za surovine.

Ni primerno dokler ni na razpolago scenarijev izpostavljenosti za surovine.

Datum izdaje/Datum

revidirane izdaje

:

5/13

21 Januar 2014

P3-topax ECO

Varovanje rok

(EN 374)

Če se na osnovi ocene tveganja ugotovi, je potrebno uporabljati ustrezno

nameščen respirator s prečiščevanjem zraka ali respirator z dovodom zraka, ki je

skladen z odobrenim standardom. Izbira respiratorja naj temelji na znanih in

pričakovanih nivojih izpostavitve, nevarnosti proizvoda in delovnih omejitvah

respiratorja.

Zelo priporočljivo : Rokavice - butilna guma , nitrilna guma ( čas prodiranja: 1 - 4

ure ) .

Zelo priporočljivo : Varovalna očala, ščitnik za obraz ali ostala zaščita za ves obraz.

Zaščitoza oči/obraz

(EN 166)

Zaščita dihal

(EN 143, 14387)

:

:

:

Varovanje kože

Osebno zaščitno opremo za telo je potrebno izbrati na podlagi vrste dela, ki se

izvaja, in tveganj, ki so prisotna. To opremo mora pred ravnanjem s tem

proizvodom odobriti strokovnjak.

:

Nadzor izpostavljenosti

okolja

:

Emisije iz prezračevanja ali delovne procesne opreme je potrebno preveriti, da se

zagotovi skladnost z zahtevami zakonodaje o varovanju okolja. V nekaterih

primerih bodo za znižanje emisij na sprejemljivo raven potrebne naprave za

čiščenje hlapov, filtri ali inženirske modifikacije na procesni opremi.

Ustrezen tehnično-

tehnološki nadzor

:

Če pri delu s proizvodom nastaja prah, dim, plin, hlapi ali meglica, je potrebno

delovni proces fizično omejiti, zagotoviti lokalno prezračevanje ali kako drugače

zagotoviti, da so izpostavitve delavcev nečistočam v zraku pod katerimikoli

priporočenimi ali predpisanimi mejnimi vrednostmi.

Po ravnanju s kemikalijami ter pred jedjo, kajenjem, uporabo stranišča in ob koncu

delovnega cikla, si temeljito umiti roke, podlakti in obraz. Primerno tehniko je

potrebno uporabiti za odstranitev potencialno onesnaženih oblačil. Oprati

onesnažena oblačila pred ponovno uporabo. Zagotoviti primerno bližino priprave

za izpiranje oči in prhe za nujne primere.

8.2 Nadzor izpostavljenosti

Higienski ukrepi

:

Za zmesi ni na razpolago DNEL vrednosti.

Predvidena koncentracija brez učinka (PNEC)

Za zmesi ni na razpolago PNEC vrednosti.

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Izpeljana raven učinka (DNEL)

Osebni zaščitni ukrepi

Zaščita telesa

(EN 14605)

:

Druga zaščita za kožo

Toplotno nevarnostjo

:

Pred postopkom se mora na podlagi dela, ki se ga opravlja in z njim povezanih

tveganj, izbrati primerno obutev in morebitne dodatne ukrepe za zaščito kože, ki jih

odobri strokovnjak.

Ni primerno.

Ime ali trgovsko ime izdelka/snovi

Mejne vrednosti izpostavljenosti

Mejne vrednosti izpostavitve pri delu

Natrijev hidroksid

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu (Slovenija,

12/2010).

MV: 2 mg/m³ 8 ur. Oblika: inhalabilna frakcija

KTV: 2 mg/m³, 4 krat na izmeno, 15 minut. Oblika: inhalabilna

frakcija

Datum izdaje/Datum

revidirane izdaje

:

6/13

21 Januar 2014

P3-topax ECO

ODDELEK 9: Fizikalne in kemijske lastnosti

Fizikalno stanje

Tališče/ledišče

Začetno vrelišče in območje vrelišča

Parni tlak

Relativna gostota

Parna gostota

Topnost

Tekočina.

1.13 do 1.17

Lahko topno v naslednjih snoveh: hladni vodi in vroči vodi.

Brez vonja.

Vonj

pH

Rumena. [svetlo]

Barva

Hitrost izparevanja

Temperatura samovžiga

Plamenišče

> 100°C

13 do 14 [Konc. (%w/w): 100%]

Viskoznost

Dinamična (sobna temperatura): 55 mPa·s

Kinematično (sobna temperatura): 0.4791219 cm

Prag vonja

Porazdelitveni koeficient: n-

oktanol/voda

Eksplozivne lastnosti

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

Brez.

Oksidativne lastnosti

:

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Izgled

9.2 Drugi podatki

Čas gorenja

Stopnja gorenja

:

:

Temperatura razkroja

:

Ni dodatnih podatkov.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno.

Zgornje/

spodnje meje vnetljivosti ali eksplozivnosti

:

Ni primerno in/ali ni določeno za zmesi.

Vnetljivost (trdno, plinasto)

:

Ni primerno in/ali ni določeno za zmesi.

10.4 Pogoji, ki se jim je

treba izogniti

Ni specifičnih podatkov.

Proizvod je stabilen.

10.2 Kemijska stabilnost

:

:

10.3 Možnost poteka

nevarnih reakcij

:

Pri normalnih pogojih skladiščenja in uporabe do nevarnih reakcij ne bo prihajalo.

ODDELEK 10: Obstojnost in reaktivnost

10.1 Reaktivnost

:

Konkretnih podatkov o preskusih v zvezi z reaktivnostjo tega izdelka ali njegovih

sestavin ni na razpolago.

10.5 Nezdružljivi materiali

:

Ni specifičnih podatkov.

Datum izdaje/Datum

revidirane izdaje

:

7/13

21 Januar 2014

P3-topax ECO

ODDELEK 10: Obstojnost in reaktivnost

10.6 Nevarni produkti

razgradnje

Pri normalnih pogojih skladiščenja in uporabe ne bi smelo prihajati do nevarnih

razkrojnih produktov.

:

Potencialno akutni vplivi na zdravje

Vdihavanje

:

Lahko sprošča pline, hlape ali prah, ki so zelo dražilni ali jedki za dihalni sistem.

Izpostavljenost produktom razkroja lahko ogrozi zdravje. Resne posledice, ki sledijo

izpostavitvi, so lahko pojavijo z zakasnitvijo.

Jedko za prebavni trakt. Povzroča opekline. Lahko povzroči opekline ust, žrela in

želodca.

:

Zaužitje

Stik s kožo

:

Povzroča hude opekline.

Povzroča hude poškodbe oči.

:

Stik z očmi

Akutna strupenost

Etilendiamintetraacetat

LD50 Oralno

Podgana

1700 mg/kg

Arilsulfonati

LD50 Dermalno

Kunec

>2000 mg/kg

LD50 Oralno

Podgana

4400 mg/kg

Ime ali trgovsko ime

izdelka/snovi

Rezultat

Vrste

Odmerek

Izpostavljenost

Rakotvornost

Mutagenost

Teratogenost

Strupenost za razmnoževanje

Simptomi, ki izvirajo iz fizikalnih, kemičnih in toksikoloških značilnosti

Dražilnost/Jedkost

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Povzroča preobčutljivost

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Ocene akutne strupenosti

Oralno

10588.6 mg/kg

Pot

Vrednost ATE

SPECIFIČNA STRUPENOST ZA CILJNE ORGANE (STOT) – ENKRATNA IZPOSTAVLJENOST

STOT – ponavljajoča se izpostavljenost

Nevarnost pri vdihavanju

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Podatki o možnih načinih

izpostavljenosti

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Datum izdaje/Datum

revidirane izdaje

:

8/13

21 Januar 2014

P3-topax ECO

ODDELEK 11: Toksikološki podatki

Potencialno kronični vplivi na zdravje

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Splošno

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Rakotvornost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Mutagenost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Teratogenost

:

Učinek na razvoj

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Učinki na plodnost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Stik s kožo

Zaužitje

Vdihavanje

Ni specifičnih podatkov.

Škodljivi simptomi lahko vključujejo naslednje:

bolečine v želodcu

Škodljivi simptomi lahko vključujejo naslednje:

bolečina ali draženje

pordelost

lahko se pojavijo mehurji

:

:

:

Stik z očmi

:

Škodljivi simptomi lahko vključujejo naslednje:

bolečina

solzenje

pordelost

Zapozneli in takojšnji učinki ter kronični učinki po kratkodobni in dolgodobni izpostavljenosti

Kratkotrajna izpostavljenost

Dolgotrajna izpostavljenost

Možni neposredni učinki

:

Možni zapozneli učinki

:

Možni neposredni učinki

:

Možni zapozneli učinki

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Drugi podatki

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

ODDELEK 12: Ekološki podatki

12.3 Zmožnost kopičenja v organizmih

12.1 Strupenost

Etilendiamintetraacetat

Akutni LC50 121 mg/L

Ribe

96 ur

Natrijev hidroksid

Akutni EC50 40 mg/L

Vodne bolhe

48 ur

Alkilaminoksidi

Akutni EC50 0.1 do 1 mg/L

Vodne bolhe

48 ur

Arilsulfonati

Akutni LC50 >100 mg/L

Ribe

96 ur

Ime ali trgovsko ime

izdelka/snovi

Vrste

Rezultat

Izpostavljenost

12.2 Obstojnost in razgradljivost

Zaključek/Povzetek

:

Vsota organskih komponent, ki jih proizvod vsebuje, doseže v testu lahke

razgradljivosti vrednosti pod 60% BPK/KPK ali sproščanje CO2 oz. pod 70% DOC-

znižanje. Mejne vrednosti za razvrščanje lahke razgradljivosti /readily degradable

(npr. OECD 301) niso dosežene.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Datum izdaje/Datum

revidirane izdaje

:

9/13

21 Januar 2014

P3-topax ECO

ODDELEK 12: Ekološki podatki

LogP

ow

BCF

Potencialno

12.6 Drugi škodljivi učinki

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ime ali trgovsko ime

izdelka/snovi

Etilendiamintetraacetat

5.01

visok

PBT

:

Ni primerno.

vPvB

:

Ni primerno.

12.4 Mobilnost v tleh

12.5 Rezultati ocene PBT in vPvB

:

Porazdelitveni koeficient

prst/voda (K

OC

)

:

Ni določeno za zmesi.

Mobilnost

:

Ni določeno za zmesi.

Evropski katalog odpadkov (EWC)

Nevarni odpadki

:

Kjerkoli je možno, se je potrebno izogniti nastajanju odpadkov, oziroma jih zmanjšati

na najmanjšo možno raven. Prazne posode ali podloge lahko zadržijo ostanke

proizvoda. Vsebina in embalaža morata biti varno odstranjeni. Znatnih količin

odpadnih ostankov proizvoda se ne sme spuščati v kanalizacijo, ampak jih je

potrebno obdelati v ustreznih čistilnih napravah. Preostanke in proizvode, ki se jih

ne da reciklirati, odstrani pooblaščeno podjetje za odstranjevanje odpadkov.

Odstranjevanje tega proizvoda, raztopin in kakršnih koli stranskih proizvodov mora

vedno potekati v skladu z zahtevami predpisov o zaščiti okolja in odstranjevanju

odpadkov oz. katerih koli drugih predpisov. Preprečiti, da bi se razlit oz. razsut tovor

razširil; preprečiti stik s tlemi, vodotoki, cestno kanalizacijo in odplakami.

:

Metode odstranjevanja

ODDELEK 13: Odstranjevanje

Informacije v tem oddelku vsebujejo splošne nasvete in napotke. Glede specifične uporabe je za podatke, ki so na

voljo v scenariju(ih) izpostavljenosti, potrebno upoštevati seznam identificiranih uporab v Oddelku 1.

13.1 Metode ravnanja z odpadki

Proizvod

Pakiranje

Šifra odpadka

Oznaka odpadka

Metode odstranjevanja

:

Posebni previdnostni

ukrepi

:

20 01 15*

alkalije

Kjerkoli je možno, se je potrebno izogniti nastajanju odpadkov, oziroma jih zmanjšati

na najmanjšo možno raven. Odpadno embalažo je potrebno reciklirati.

Vsebina in embalaža morata biti varno odstranjeni. Z izpraznjeno posodo, ki ni bila

očiščena ali splaknjena, je potrebno previdno ravnati. Prazne posode ali podloge

lahko zadržijo ostanke proizvoda. Preprečiti, da bi se razlit oz. razsut tovor razširil;

preprečiti stik s tlemi, vodotoki, cestno kanalizacijo in odplakami.

Datum izdaje/Datum

revidirane izdaje

:

10/13

21 Januar 2014

P3-topax ECO

RAZTOPINA

NATRIJEVEGA

HIDROKSIDA

SODIUM

HYDROXIDE

SOLUTION

Sodium hydroxide

solution

UN1824

RAZTOPINA

NATRIJEVEGA

HIDROKSIDA

UN1824

UN1824

UN1824

ODDELEK 14: Podatki o prevozu

ADR/RID

IMDG

IATA

14.1 UN številka

14.2 UN Uradno

ime blaga

14.3 Razredi

nevarnosti

prevoza

14.4 Embalažna

skupina

ADN/ADNR

14.5 Okolju

nevarno

14.6 Posebni

previdnostni

ukrepi za

uporabnika

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II

k MARPOL 73/78 in

Kodeksom IBC

:

Ni primerno.

Brez.

Brez.

None.

None.

Državni predpisi

Drugi predpisi EU

Ni primerno.

Priloga XVII - Omejitve

proizvodnje, dajanja v

promet in uporabe

nekaterih nevarnih snovi,

pripravkov in izdelkov

:

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

Uredba ES (ES) št 1907/2006 (REACH)

Priloga XIV - Seznam snovi, ki so predmet avtorizacije

15.2 Ocena kemijske

varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

Snovi, ki vzbujajo zelo veliko zaskrbljenost

:

Nobene od sestavin ni na seznamu.

≥15 - <30% EDTA

<5% neionski tenzidi

Navedba sestavin v skladu z Uredbo o detergentih 648/2004/EC:

Slovenija

Datum izdaje/Datum

revidirane izdaje

:

11/13

21 Januar 2014

P3-topax ECO

21 Januar 2014

Datum tiskanja

:

Celotno besedilo okrajšanih

stavkov R

:

R20/22- Zdravju škodljivo pri vdihavanju in pri zaužitju.

R35- Povzroča hude opekline.

R41- Nevarnost hudih poškodb oči.

R36- Draži oči.

R38- Draži kožo.

R50- Zelo strupeno za vodne organizme.

C - Jedko

Xn - Zdravju škodljivo

Xi - Dražilno

N - Okolju nevarno

:

Celotno besedilo razvrstitev

[DSD/DPD]

Prikazuje informacijo, ki se je spremenila od prejšnje izdaje.

ODDELEK 16: Drugi podatki

Celotno besedilo okrajšanih

stavkov H

:

Okrajšave in akronimi

:

ADN = Evropski sporazum o mednarodnem prevozu nevarnih snovi po celinskih

vodah/po Renu

ADR = Evropski sporazum o mednarodnem cestnem prevozu nevarnega blaga

ATE = ocena akutne strupenosti

BCF = biokoncentracijski faktor

CLP = Uredba (ES) št. 1272/2008 o razvrščanju, označevanju in pakiranju snovi ter

zmesi

DNEL = Izpeljana raven brez učinka

DPD = Direktiva Sveta EU [1999/45/EC] o razvrščanju, pakiranju in označevanju

nevarnih pripravkov

EC = evropska komisija

EUH = CLP - specifičen stavek nevarnosti

IATA = Mednarodno združenje letalskih prevoznikov

IBC = vsebnik IBC

IMDG = Mednarodni kodeks o prevozu nevarnega blaga po morju

LogPow = logaritem porazdelitvenega koeficienta oktanol/voda

MARPOL 73/78 = Mednarodna konvencija o preprečevanju onesnaževanja morja z

ladij, 1973, in njen Protokol iz leta 1978

OEL = mejna vrednost za poklicno izpostavljenost

PBT = Obstojen, bioakumulativen in strupen

PNEC = predvidena koncentracija brez učinka

REACH = Registracija, Evalvacija, Avtorizacija in omejevanje Kemikalij [Uredba (ES)

št. 1907/2006]

RID = Pravilnik o mednarodnem železniškem prevozu nevarnega blaga

REACH # = Registracijska številka REACH

vPvB = zelo obstojen in zelo bioakumulativen

Postopek, po katerem se je določilo razvrstitev po uredbi (ES) št. 1272/2008 [CLP/GHS]

Razvrstitev

Utemeljitev

Skin Corr. 1, H314

Na osnovi testnih podatkov

Celotno besedilo razvrstitev

[CLP/GHS]

:

H302

Zdravju škodljivo pri zaužitju.

H314

Povzroča hude opekline kože in poškodbe oči.

H315

Povzroča draženje kože.

H318

Povzroča hude poškodbe oči.

H319

Povzroča hudo draženje oči.

H400

Strupeno za vodne organizme.

Acute Tox. 4, H302

AKUTNA STRUPENOST: ORALNO - Kategorija 4

Aquatic Acute 1, H400

NEVARNO ZA VODNO OKOLJE (AKUTNO) - Kategorija

Eye Dam. 1, H318

HUDA POŠKODBA OČI/DRAŽENJE OČI - Kategorija 1

Eye Irrit. 2, H319

HUDA POŠKODBA OČI/DRAŽENJE OČI - Kategorija 2

Skin Corr. 1, H314

JEDKOST ZA KOŽO/DRAŽENJE KOŽE - Kategorija 1

Skin Corr. 1A, H314

JEDKOST ZA KOŽO/DRAŽENJE KOŽE - Kategorija 1A

Skin Irrit. 2, H315

JEDKOST ZA KOŽO/DRAŽENJE KOŽE - Kategorija 2

Datum izdaje/Datum

revidirane izdaje

:

12/13

21 Januar 2014

P3-topax ECO

ODDELEK 16: Drugi podatki

Datum izdaje/ Datum

revidirane izdaje

Verzija

Za posredovane podatke verjamemo, da so pravilni glede na formulacijo uporabljeno za proizvodnjo izdelka v

državi porekla. V primeru, da se podatki, standardi ali zakonodaja spremenijo, kakor tudi pogoji uporabe ter

rokovanja, ki so izven našega nadzora, NE DAJEMO NOBENEGA JAMSTVA, IZRAŽENEGA ALI NAZNAČENEGA,

GLEDE CELOVITOSTI ALI NEOKRNJENE TOČNOSTI NAVEDENIH PODAKOV.

Obvestilo bralcu

Datum prejšnje izdaje

:

:

:

21 Januar 2014

Ni prejšnje validacije

Datum izdaje/Datum

revidirane izdaje

:

13/13

21 Januar 2014

16-11-2018

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Evaluation of confirmatory data following the Article 12 MRL review for pyraclostrobin

Published on: Thu, 15 Nov 2018 The applicant BASF SE submitted a request to the competent national authority in Germany to evaluate the confirmatory data that were identified for pyraclostrobin in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005 as not available. To address the data gaps, residues trials supporting the existing use of pyraclostrobin on table grapes authorised in southern EU Member States and an analytical method for analysing residues of pyraclostrobin in ...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Recommendations on the use of the proportionality approach in the framework of risk assessment for pesticide residues

Published on: Wed, 14 Nov 2018 The technical report reflects the outcome of the discussions and agreements that were reached in the pesticides peer review meeting on residues and maximum residue levels regarding the principles and guidance for application of the proportionality concept in the risk assessment methodologies used at European level for the estimation of the maximum residue levels for pesticides. In addition, practical experiences on the use of the proportionality approach gained by EFSA hav...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

13-11-2018

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA Publishes Design Recommendations for Residue Studies in Honey

FDA published draft guidance for industry #243 “Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing MRLs and Withdrawal Periods.”

FDA - U.S. Food and Drug Administration

6-11-2018

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Setting of import tolerances for haloxyfop‐P in linseed and rapeseed

Published on: Fri, 02 Nov 2018 00:00:00 +0100 In accordance with Article 6 of Regulation (EC) No 396/2005, the Australian Government Department of Agriculture and Water Resources submitted two requests to the competent national authority in Denmark to set import tolerances for the active substance haloxyfop‐P in linseed and rapeseed. The data submitted in support of the request were found to be sufficient to derive maximum residue level (MRL) proposals for linseed and rapeseed. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

24-10-2018

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Safety and efficacy of Hostazym® X (endo‐1,4‐beta‐xylanase) as a feed additive for sows in order to have benefit in piglets

Published on: Tue, 23 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of HOSTAZYM® X as a feed additive for sows in order to have benefit in piglets. The additive HOSTAZYM® X contains endo‐1,4‐beta‐xylanase and is available in liquid and solid formulations. This product is authorised as a feed additive for chickens for fattening, tu...

Europe - EFSA - European Food Safety Authority Publications

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

10-10-2018

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

Tanning booths: ANSES issues a reminder of the proven risk of skin cancer

The health risks associated with exposure to artificial UV radiation from tanning booths have been well established for many years now. ANSES points out that recent data on the subject support previous assessments: there is a proven cancer risk associated with UV radiation from artificial tanning equipment. The Agency therefore recommends that the public authorities take the necessary steps to prevent people from being exposed to artificial UV radiation from tanning booths used for cosmetic purposes.

France - Agence Nationale du Médicament Vétérinaire

21-9-2018

Scientific guideline:  Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

Scientific guideline: Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

This document provides a standard approach to be used across the European Union in the analysis of residue depletion data for the purpose of establishing withdrawal periods for edible tissues. Emphasis has been put on a statistical approach. As the method of first choice, a linear regression technique is recommended. A computerised version of the method described is available: Updated application software: withdrawal time calculation for tissues. Read together with the explanatory note on updated applica...

Europe - EFSA - European Food Safety Authority EFSA Journal

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EFSA Panel on Plant Protection Products and their Residues reviewed the guidance on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessment. The inclusion of aged sorption is a higher tier in the groundwater leaching assessment. The Panel based its review on a test with three substances taken from a data set provided by the European Crop Protection Association. Particular points of attention were the quali...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 This report describes the framework of collection, management and transmission of food safety data in the Federal Republic of Germany. To adjust optimally the data governance processes to the requirements defined by the EFSA, measures had been agreed upon in order to improve the specified situation. Subsequent methodological system enhancements related to data quality are given as well as structural adjustments and the development and implementation of suppo...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

The EU's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted new recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones (bone metastases). Xofigo should only be used in symptomatic patients who have had two previous treatments for prostate cancer and who cannot be treated with other medicines.

Danish Medicines Agency

23-8-2018

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

6-8-2018

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment drugs to treat opioid use disorder.

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

20-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

FDA posted a new batch of 43 product-specific guidances related to the development of generic drug products that includes three revised product-specific guidances for ADF opioid products. These guidances recommend specific in vivo studies and in vitro study considerations for abuse deterrence evaluations.

FDA - U.S. Food and Drug Administration

19-7-2018

Assessment of the safety of feminine hygiene products

Assessment of the safety of feminine hygiene products

Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...

France - Agence Nationale du Médicament Vétérinaire

18-7-2018

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

In a context where prevention of ambient air pollution is a real public health issue, questions are regularly asked about the value of recommending that the population wear personal protective equipment. This led ANSES to assess the potential health benefits of wearing "anti-pollution" masks. Its expert appraisal revealed a lack of data demonstrating a health benefit. To reduce the health impacts associated with ambient air pollution, the Agency reiterates the importance of prioritising action at the sou...

France - Agence Nationale du Médicament Vétérinaire

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

4-7-2018

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Cases of skin allergies and irritation related to clothing or footwear are regularly reported to the health authorities. Today ANSES is publishing the results of the expert appraisal it conducted to identify the chemicals likely to be found in these articles and possibly responsible for these cases. Further to this expert appraisal, the Agency is issuing recommendations on how to better protect consumers from the risks of skin allergies and irritation caused by the presence of these substances.

France - Agence Nationale du Médicament Vétérinaire

28-6-2018

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

The European monitoring strategy for air quality relies heavily on quality standards for a number of pollutants. Advances in knowledge on the toxicity of substances and their emissions in the atmosphere have shown that certain pollutants that may have an impact on human health are not currently taken into account in regulatory monitoring. ANSES therefore received a formal request from the Ministries of Ecology and Health to propose a list of new priority pollutants for this air quality monitoring to supp...

France - Agence Nationale du Médicament Vétérinaire

8-5-2018

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

The FDA has received reports associated with the use of these devices in the treatment of unruptured brain aneurysms that suggest some events of peri-procedural stroke and/or death may have been related to procedural risks or patient selection related factors. These factors include patients who had serious co-morbidities resulting in a reduced life expectancy, or who were intolerant to required anticoagulation or anti-platelet therapy.

FDA - U.S. Food and Drug Administration

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

15-2-2018

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

The Danish Medicines Agency recommends doctors not to start any new patients on the medicine Esmya (ulipristal) because of a rare, but possible, risk of developing serious liver injury.

Danish Medicines Agency

14-11-2017

The European Commission has published three recommendations for the clinical trials regulation

The European Commission has published three recommendations for the clinical trials regulation

In cooperation with the clinical trials expert group, the European Commission is updating and issuing new recommendations as a result of the regulation on clinical trials on medicinal products for human use.

Danish Medicines Agency

21-3-2017

New recommendation for phasing out zinc oxide for young pigs

New recommendation for phasing out zinc oxide for young pigs

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has confirmed a previous decision to phase out zinc oxide. Consequently, the CVMP has once more recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

19-12-2016

Zinc oxide for young pigs to be phased out

Zinc oxide for young pigs to be phased out

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

20-7-2016

Marketing authorisation for medicine for cows suspended in the EU/EEA

Marketing authorisation for medicine for cows suspended in the EU/EEA

On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.

Danish Medicines Agency

17-10-2014

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

The EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) recommends strengthening the restrictions on the use of the antiepileptic valproate due to the risk of malformations and developmental problems in children exposed to valproate in the womb.

Danish Medicines Agency

3-10-2014

Consultation procedure about medicinal products and safety measure requirements not completed yet

Consultation procedure about medicinal products and safety measure requirements not completed yet

On 5 September 2014, the Danish Health and Medicines Authority submitted a draft list of the medicinal products comprised by the new safety measures rules (Directive 2001/83) for consultation. The consultation period expired on 17 September 2014, and on 3 October we were to inform the European Commission of the medicinal products we recommend including in the common EU lists. We have received 22 consultation responses. But on 24 September 2014 the European Commission amended the original guideline for...

Danish Medicines Agency

25-2-2014

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

The European Medicines Agency (EMA) recommends to restrict the use of the osteoporosis medicine strontium ranelate (Protelos®) to patients with severe osteoporosis who cannot be treated with other medicines approved for osteoporosis.

Danish Medicines Agency

5-1-2012

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.

Danish Medicines Agency

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

1-12-2011

Danish Pharmacovigilance Update, 17 November 2011

Danish Pharmacovigilance Update, 17 November 2011

In this issue of Danish Pharmacovigilance Update, you can read about domperidone (Motilium® etc.) and potential risk of cardiac disorders, about the European Medicines Agency's recommendation on a lower dose of the antidepressant citalopram as well as about more interesting aspects of pharmacovigilance.

Danish Medicines Agency

4-11-2011

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.

Danish Medicines Agency

26-8-2011

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.

Danish Medicines Agency

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

27-5-2011

Consultation on the Reimbursement Committee's recommendation for glucosamine

Consultation on the Reimbursement Committee's recommendation for glucosamine

The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.

Danish Medicines Agency

6-5-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.

Danish Medicines Agency

21-10-2018

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting  ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting https://go.usa.gov/xPnyd .

FDA - U.S. Food and Drug Administration

9-10-2018

#ICYMI - FDA issues recommendations to help prevent surgical fires and      related patient injury. Click the link to read the recommendations:  https://go.usa.gov/xQdwG   #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

Click the link for a handy list of #FDA’s recommendations for using and  caring for your medical devices during a #hurricane.   https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

6-8-2018

Scientific guideline:  ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

Scientific guideline: ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide rec...

Europe - EMA - European Medicines Agency

18-7-2018

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity:  https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://healthsectorcouncil.org/health-sector-mobilizes-against-cyber-threats/ …

FDA - U.S. Food and Drug Administration

16-7-2018

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Active substance: Fluoxetine) - Centralised - Renewal - Commission Decision (2018)4770 of Mon, 16 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/133/R-18

Europe -DG Health and Food Safety

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

29-5-2018

FDA issues recommendations to help prevent surgical fires and related patient injury-  https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA - U.S. Food and Drug Administration